JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Herpes zoster and dementia : more evidences for a causal link	611
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	131
Gene and genetic therapies in Alzheimer’s disease and other dementias	131
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	116
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	90
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	88
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	83
Lecanemab over a two-year duration: Key insights from a regional specialty medical center	78
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	67
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	65
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	62
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	56
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status	54
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	46
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	46
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study	42
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	42
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	40
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	40
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	39
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	38
Introduction to the Special Issue on the A4 Study	38
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	37
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	35
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	32

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	31
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	30
Informal care for people with dementia in Europe	30
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	30
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	30
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	29
Content	29
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	29
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	28
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	27
Donanemab: Appropriate use recommendations	27
Editorial Board	25
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	25
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	25
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	24
Multi-modal data analysis for early detection of alzheimer’s disease and related dementias	24
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	24
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	23
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease	23
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	23
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	22
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	22
Treatments for Alzheimer’s and the declaration of Helsinki	22
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	21
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	21
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	21
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	21
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	21
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	21
Living arrangements and cognitive resilience in aging: unraveling distinct pathways through plasma biomarkers	21
Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension	21
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	20
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	20
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	19
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	19
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	19
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	19
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	19
What can artificial intelligence bring to Alzheimer’s disease clinical trials? A first perspective	19
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	19
Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults	18
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	18
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	18
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	18
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	18
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	18
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study	18
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	18
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	17
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	17

Association of life’s simple 7 with cognitive function in a multi-ethnic cohort	17
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	17
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	17
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	17
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	17
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	17
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	17
Clarifying what BP Predicts: Commentary on CSF Aβ42/40, p-tau181, and centiloid in unimpaired populations	17
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	16
Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease	16
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	16
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	16
Predicting cognitive decline: Comparative analysis of ANU-ADRI, CAIDE, CogDrisk, LIBRA, LIBRA2, UKBDRS and Lancet based dementia risk scores in the HUNT study	16
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	16
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	16
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	15
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	15
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	15
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	15
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease	15
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	15
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	15
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	15
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	14
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	14
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	14
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	14
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	14
Artificial intelligence and the acceleration of Alzheimer’s research - From promise to practice	13
Editorial Board	13
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	13
Iron dysregulation in cerebral small vessel disease: A quantitative susceptibility mapping study revealing spatial patterns and cognitive predictive value	13
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	13
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	13
Editorial Board	13
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	13
Sociodemographic differences in dementia prevention knowledge in Germany: Implications for targeted health communication	13
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	13
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	13
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	13
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	12
Integrative SMR prioritizes oxidative stress–related regulatory genes for Alzheimer’s disease with brain-tissue validation	12
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	12
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	12
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	12
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	12
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	12
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic	12
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	12
Tau in Alzheimer's disease: Shaping the future patient journey	12
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	12
It’s time to address the recruitment bottleneck	12
Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice	12
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	12
AI models, bias and data sharing efforts to tackle Alzheimer's disease and related dementias	12
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	12
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	12
Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease	12
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	12
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	12
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	12
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	12
Alzheimer’s disease prevention by flavonols and their analogs	12
Add-on combination therapy with monoclonal antibodies: Implications for drug development	12
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	11
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	11
Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	11
The Future is Now: Advancing Blood-Based Markers	11
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	11
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	11
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	11
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	11
The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study	10
Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial	10
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	10
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	10
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	10
Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study	10
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	10
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	10

Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	10
Association between plant-based diets and incident dementia: results from prospective cohort studies and a meta-analysis	10
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	10
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	10
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	10
Content	10
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	10
Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer’s disease	10
The Dawn of a New Era of Alzheimer's Research and Drug Development	10
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	10
Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial	10
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	9
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	9
Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review	9
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	9
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	9
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	9
The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease	9
Early-Onset Type 2 Diabetes and Risk of Dementia	9
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	9
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	9
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	9
Evaluating evidence-based recruitment strategies for Alzheimer’s disease and related dementias clinical trial research: A literature review	9
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	9
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	9
Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI	9
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	9
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	9
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	9
Spatial amyloid–informed multimodal brain age as an early marker of Alzheimer’s-related vulnerability and risk stratification	9
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	9
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration	9
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	9
Microglial activation states and their implications for Alzheimer's Disease	9
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	9
Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	9
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	8
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	8
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	8
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	8
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial	8
Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool	8
Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial	8
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress	8
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia	8
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	8
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	8
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	8
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	8
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	8
Appropriate Use Recommendations for Lecanemab	8
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges	8
Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study	8
Eligibility for donanemab trial in a population-based study of cognitive aging	8
Brain health PRO/santé cerveau PRO: The development of a web-based program for dementia literacy and risk factor reduction	8
Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies	8
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults	8
Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort	8
Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer’s disease	8
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography	8
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials	8
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease	8
Medical risk factors, ApoE haplotype, and Alzheimer’s disease: a large-scale analysis	8
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study	8
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies	8
Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication	8